Welcome! You are visiting the MyeloRx web site.
Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
MRx102
Cell Line (IC
50
nM)
Jurkat (Human T
Cell Lymphoma)
1
MV4-11
(Human AML)
2
Natural Product
74
102
MRx102
93
133
Percent (%)
80
76
1 - preincubation with human plasma
2 - no preincubation
All rights reserved
Powered by
Microsoft Office Live Small Business